Skip to main content

Advertisement

SpringerLink
Log in

The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer

  • Review Article
  • Published:
Hellenic Journal of Surgery

Abstract

The aim of this literature review was to derive detailed information on the indications for sentinel lymph node biopsy (SLNB) in specific subgroups of patients with breast cancer, according to current evidence, in an era when the dogma of complete axillary lymph node dissection (ALND) is being challenged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SLNB:

Sentinel lymph node biopsy

ALND:

Axillary lymph node dissection

DCIS:

In situ ductal carcinoma

IR:

Identification rate

FNR:

False negative rate

ASCO:

American Society of Clinical Oncology

NCCN:

National Comprehensive Cancer Network

ESMO:

European Society of Medical Oncology

pCR:

Complete pathological response

DFS:

Disease free survival

OS:

Overall survival

IHC:

Immunohistochemistry

AMAROS:

After mapping of the axilla: radiotherapy or surgery

ACOZOG Z0011:

American College of Surgeons Oncology Group Z0011

MBq:

Megabecquerel (units of radiation dose)

References

  1. Sackey H, Magnuson A, Sandelin K, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. Br J Surg. 2014;101:390–7.

    Article  CAS  PubMed  Google Scholar 

  2. Diepstraten SC, Sever AR, Buckens CF, et al. Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: A systematic review and meta-analysis. Ann Surg Oncol 2014;21:51–9.

    Article  PubMed  Google Scholar 

  3. Cooper KL, Meng Y, Harnan S, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: Systematic review and economic evaluation. Health Technol Asses. 2011;15:1–134.

    Article  Google Scholar 

  4. Houssami N, Diepstraten SCE, Cody HS, et al. Clinical utility of ultrasound-needle biopsy for preoperative staging of the axilla in invasive breast cancer. Anticancer Res 2014;34:1087–97.

    PubMed  Google Scholar 

  5. Reimer T, von Minckwitz G, Loibl S, et al. Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77:04–02.

    Google Scholar 

  6. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node vs Observation after axillary UltraSouND). Breast Edinb Scotl 2012;21:678–81.

    Article  Google Scholar 

  7. Chen Y, Zhang Y, Yang W, et al. Accuracy of a nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients. Medicine (Baltimore) 2018;97:e11273.

    Article  Google Scholar 

  8. Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized t. Ann Surg 2016;264: 413–20.

    Article  PubMed  Google Scholar 

  9. Donker M, Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): A randomized, multicenter, open-label, phase 3 non inferiority trial The Lancet 2014;15:1303–10.

    Article  PubMed  Google Scholar 

  10. Farrel TPJ, Adams NC, Stenson M, et al. The Z0011 Trial: Is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients? Eur Radiol 2015;25:2682–7.

    Article  Google Scholar 

  11. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014;32:1365.

    Article  PubMed  Google Scholar 

  12. Lim GH, Upadhaya VS, Acosta HA, et al. Preoperative predictors of high and low axillary node burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J of Surg Oncol 2018;44:945–50.

    Article  Google Scholar 

  13. Hieken TJ, Trull BC, Boughey JC, et al. Preoperative axillary imaging with percutaneous lymph node biopsy is valuable in the contemporary management of patients with breast cancer. Surgery 2013;154:831–40.

    Article  PubMed  Google Scholar 

  14. Boland MR, Prichard RS, Daskalova I, et al. Axillary nodal burden in primary breast cancer patients with positive preoperative ultrasound guided fine needle aspiration cytology: Management in the era of ACOSOG Z0011. Eur J Surg Oncol 2015;41:559–65.

    Article  CAS  PubMed  Google Scholar 

  15. Ahmed M, Jozsa F, Baker R, et al. Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients. Breast Cancer Res Treat. 2017 Nov; 166:329–36.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Van Wely BJ, de Wilt JH, Francissen C, et al. Meta analysis of ultrasound guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumor burden in breast cancer. Br J Surg 2015;102:159.

    Article  PubMed  Google Scholar 

  17. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456–66.

    Article  CAS  PubMed  Google Scholar 

  18. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9.

    Article  CAS  PubMed  Google Scholar 

  19. Benson J. Indocyanine green fluorescence for sentinel lymph node detection in early breast cancer. Ann Surg Oncol 2016;23:6–8.

    Article  PubMed  Google Scholar 

  20. Zada A, Peek MC, Ahmed M, et al. Meta-analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique. Br J Surg 2016;103:1409–19.

    Article  CAS  PubMed  Google Scholar 

  21. Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early stage breast cancer: American society of clinical oncology practice guideline update. J Clin Oncol 2017 10;35:561–4.

    Article  Google Scholar 

  22. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study. Lancet Oncol 2006;7:983–90.

    Article  PubMed  Google Scholar 

  23. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised phase III trial. National Surgical Adjuvant Breast and Bowel Project. Lancet Oncol 2007;8:881–8.

    CAS  PubMed  Google Scholar 

  24. Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): A randomized controlled surgical trial. Ann Surg Oncol 2009;16:266–75.

    Article  PubMed  Google Scholar 

  25. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella-GIVOM Italian randomised clinical trial. GIVOM. Eur J Surg Oncol 2008;34:508–13.

    Article  PubMed  Google Scholar 

  26. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.

    Article  PubMed  Google Scholar 

  27. Ahn SK, Kim J, Lee E, et al. Can we skip intraoperative evaluation of sentinel lymph nodes? Nomogram predicting involvement of three or more axillary lymph nodes before breast cancer surgery. Cancer Res Treat 2017;49:1088–96.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Groen EJ, Elshof LE, Fisher B, et al. Finding the balance between over-and under-treatment of ductal carcinoma in situ (DCIS). Breast 2017;31:274–83.

    Article  PubMed  Google Scholar 

  29. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478–88.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core needle biopsy: Meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119.

    Article  PubMed  Google Scholar 

  31. Kothari MS, Rusby JE, Agusti AA, et al. Sentinel lymph node biopsy after previous axillary surgery: A review. Eur J Surg Oncol 2012;38:8–15.

    Article  CAS  PubMed  Google Scholar 

  32. Maaskant-Braat AJG, Voogd AC, Roumen RMH, et al. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: A systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2013;138:13–20.

    Article  PubMed  Google Scholar 

  33. Vugts G, Maaskant-Braat AJG, Voogd AC, et al. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer. Breast Cancer Res Treat 2015;153:549–56.

    Article  CAS  PubMed  Google Scholar 

  34. Ahmed M, Baker R, Rubio IT. Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer. Br J Surg 2016;103:1579.

    Article  CAS  PubMed  Google Scholar 

  35. Renaudeau C, Lefebvre-Lacoeuille C, Campion L, et al. Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast 2016;28:54–9.

    Article  CAS  PubMed  Google Scholar 

  36. Borgstein PJ, Meijer S, Pijpers RJ, et al. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: Echoes from the past and the periareolar blue method. Ann Surg 2000;232:81–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Schröder L, Roland F, Roland GS, et al. Evaluation of sentinel lymph node biopsy prior to axillary lymph node dissection: The role of isolated tumor cells/micrometastases and multifocality/multicentricity—a retrospective study of 1214 breast cancer patients. Arch Gynecol Obstet 2018;297:1509–15.

    Article  PubMed  Google Scholar 

  38. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: Adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol 2015;1:1145–53.

    Article  PubMed  Google Scholar 

  39. Martin Marcuartu JJ, Alvaez-Perez RM, Sousa Vaquero JM, et al. Selective sentinel lymph node biopsy in male breast cancer. Rev Esp de Med Nucl 2018;37:146–50.

    CAS  Google Scholar 

  40. Steenbruggen TG, van Ramshorst MS, Kok M, et al. Neoadjuvant therapy for breast cancer: Established concepts and emerging strategies. Drugs 2017;77:1313–36.

    Article  CAS  PubMed  Google Scholar 

  41. Leenders MW, Broeders M, Croese C, et al. Ultrasound and fine needle aspiration cytology of axillary lymph nodes in breast cancer. To do or not to do? Breast 2012;21:578–83.

    CAS  Google Scholar 

  42. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicenter cohort study. Lancet Oncol 2013;14:609–18.

    Article  PubMed  Google Scholar 

  43. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:726–32.

    Article  Google Scholar 

  44. Van Der Heiden-Van Der Loo M, De Munck L, Sonke GS, et al. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. Eur J Cancer 2015;51:915–21.

    Article  PubMed  Google Scholar 

  45. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009;250:558–66.

    Article  PubMed  Google Scholar 

  46. Classe JM, Loaec C, Alran S, et al. Sentinel node detection after neoadjuvant chemotherapy in patients without previous axillary node involvement (GANEA 2 trial): Follow up of a prospective multi-institutional cohort. Cancer Res 2017;77:2–7.

    Google Scholar 

  47. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol 2012;30:3960–6.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: Breast cancer, version 1.2017. J Natl Compr Cancer New JNCCN 2017;15:433–51.

    Article  Google Scholar 

  50. Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol 2018;25:1488–94.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Jatoi I, Benson JR, Toi M, et al. De-escalation of axillary surgery in early breast cancer. Lancet Oncol 2016;17:430–41.

    Article  Google Scholar 

  52. Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastu-zumab for HER2-positive breast cancer. Cancer 2010;116:2884–9.

    Article  PubMed  Google Scholar 

  53. Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: Results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol 2015;33:3386–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Boughey JC, Suman VJ, Mittebdorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (alliance) clinical trial. JAMA 2013;310:1455–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance). Ann. Surg 2016;263:802–7.

    Article  PubMed  Google Scholar 

  56. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven nodepositive breast cancer: The SN FNAC study. J Clin Oncol 2015;33:258–64.

    Article  PubMed  Google Scholar 

  57. Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically nodenegative or node-positive disease before treatment. Eur J Surg Oncol 2016;42:361–8.

    Article  CAS  PubMed  Google Scholar 

  58. Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 2016;23:3467–74.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Zetterlund L, Celebioglu F, Axelsson R. Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. Breast Ca Res and Treat 2017;163:93–101.

    Article  Google Scholar 

  60. El Hage Chehade H, Headon H, El Tokhy O. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node positive breast cancer at diagnosis. An updated metaanalysis involving 3398 patients. Am J Surg 2016;212:969–81.

    Google Scholar 

  61. Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: The MARI procedure. Ann Surg 2015;261:378–82.

    Article  PubMed  Google Scholar 

  62. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol 2016;34:1072–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Genesis Hospital, Thessaloniki, Greece

    Sofia E Triantafillidou

Authors
  1. Sofia E Triantafillidou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofia E Triantafillidou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Triantafillidou, S.E. The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer. Hellenic J Surg 90, 186–194 (2018). https://doi.org/10.1007/s13126-018-0469-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13126-018-0469-8

Key words

Search

Navigation